These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28125180)

  • 21. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Tang Y; Wang K; Shi Z; Yang P; Dang X
    Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacoeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department.
    Law S; Ghag D; Grafstein E; Stenstrom R; Harris D
    CJEM; 2016 Sep; 18(5):340-8. PubMed ID: 27618975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Home treatment of deep venous thrombosis in the era of new oral anticoagulants.
    Stein PD; Matta F; Hughes PG; Ghiardi M; Marsh JH; Khwarg J; Brandon MS; Fowkes HA; Kazan V; Wiepking M; Keyes DC; Kakish EJ; Hughes MJ
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):729-32. PubMed ID: 26239315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin.
    de Athayde Soares R; Matielo MF; Brochado Neto FC; Nogueira MP; Almeida RD; Sacilotto R
    Surgery; 2019 Dec; 166(6):1076-1083. PubMed ID: 31277885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism.
    Türk M; Aldağ Y; Oğuzülgen İK; Ekim N
    Tuberk Toraks; 2016 Sep; 64(3):198-205. PubMed ID: 28393726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
    Seaman CD; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
    Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center.
    Sargin M; Erdogan SB; Bastopcu M; Arslanhan G; Tasdemir MM; Orhan G
    Value Health Reg Issues; 2019 Sep; 19():81-86. PubMed ID: 31254969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome.
    Jeraj L; Jezovnik MK; Poredos P
    Thromb Res; 2017 Sep; 157():46-48. PubMed ID: 28692839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis].
    Kalinin RE; Suchkov IA; Pshennikov AS; Agapov AB
    Khirurgiia (Mosk); 2016; (2):61-65. PubMed ID: 26977870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Medication Adherence and Treatment Persistence between New Oral Anticoagulant and Warfarin among Patients.
    Lai YF; Neo JK; Cheen MH; Kong MC; Tai BC; Ng HJ
    Ann Acad Med Singap; 2016 Jan; 45(1):12-7. PubMed ID: 27118224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical experience with the use of rivaroxaban in the treatment of cancer patients with venous thrombosis].
    Kravtsov PF; Katorkin SE; Melnicov MA
    Khirurgiia (Mosk); 2018; (1):57-63. PubMed ID: 29376959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
    Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
    Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.